Researchers in Bangladesh have found that severe cholera in children can be treated effectively with a single dose of the antibiotic ciprofloxacin, according to a study published online by The Lancet.
Cholera is a major global health problem particularly in children in areas in less-developed countries. In the resource-limited countries where cholera occurs, any reduction in hospital stay is important as it reduces the demands on the healthcare system. Currently, WHO recommends a three-day, 12-dose course of antibiotic treatment with either tetracycline or erythromycin for treatment of cholera in children.
Debasish Saha, of the Centre for Health and Population Research in Bangladesh, and colleagues compared the effectiveness of a three-day, 12-dose course of erythromycin with a single-dose of ciprofloxacin. One hundred sixty-two children were randomly assigned to treatment with either ciprofloxacin or erythromycin. Treatment with ciprofloxacin was successful within 48 hours in 60 percent of cases, compared with 55 percent in children who were treated with erythromycin. Ciprofloxacin was more effective than erythromycin at reducing vomiting and stool number and volume. However, single-dose ciprofloxacin was inferior to erythromycin in eradicating the cholera bacteriaVibrio choleraeresulting in those treated with ciprofloxacin excreting the bacteria for longer than those treated with erythromycin.
Saha concludes, For infections caused by susceptible strains of V cholerae, single-dose ciprofloxacin achieves clinical outcomes similar to or better than, those achieved with 12-dose erythromycin treatment in childhood cholera, but is less effective in eradicating V cholerae from stool.
Source: The Lancet
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.